Browse the corpus

Disease-modifying antirheumatic drugs (DMARDs) are a class of immunomodulatory agents indicated for the treatment of inflammatory arthritides such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, as well as connective tissue diseases and select malignancies. This activity reviews the core pharmacologic principles of DMARD therapy, including mechanisms of action, administration, adverse effect profiles, and drug interactions. This activity primarily focuses on the classification of DMARDs, including conventional synthetic, biologic, and targeted synthetic agents, as well as the rationale behind agent selection in various clinical contexts. Additionally, this activity reviews with specific emphasis on monitoring protocols, including laboratory surveillance, ophthalmologic screening, and vaccination planning. Participants also gain insight into contraindications during pregnancy, renal or hepatic impairment, and infection risk. Understanding the intricate pharmacology of DMARDs empowers healthcare professionals to tailor treatment plans to individual patient needs. This knowledge allows for informed decision-making when prescribing DMARDs and optimizing dosage regimens while minimizing adverse reactions. The emphasis lies on empowering healthcare professionals, emphasizing the essential role of the interprofessional healthcare team in managing DMARD therapy. This activity aims to equip healthcare professionals with the fundamental knowledge and tools necessary for delivering excellent patient care during DMARD administration, thereby advancing patient outcomes and care standards. Overall, this comprehensive activity enables healthcare professionals to deliver targeted, safe, and personalized care, thereby enhancing patient outcomes in rheumatoid arthritis. Objectives: Differentiate between conventional synthetic, biologic, and targeted synthetic disease-modifying antirheumatic drugs based on their mechanisms of action, pharmacologic characteristics, and therapeutic indications. Identify evidence-based indications for individual disease-modifying antirheumatic drugs in the treatment of autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, and systemic connective tissue disorders. Screen for the major contraindications of conventional and biologic disease-modifying antirheumatic drugs.

Identify evidence-based indications for individual disease-modifying antirheumatic drugs in the treatment of autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, and systemic connective tissue disorders. Screen for the major contraindications of conventional and biologic disease-modifying antirheumatic drugs. Implement effective collaboration and communication among interprofessional team members to improve patient outcomes and treatment efficacy for those who may benefit from disease-modifying antirheumatic drug pharmacotherapy. Access free multiple choice questions on this topic.

Toxicity from DMARDs is agent-specific and influenced by dosing, administration route, and comorbid conditions such as renal or hepatic impairment. Management depends on the severity and organ involvement, with specific agents requiring targeted interventions. Methotrexate Low-dose methotrexate may cause mucositis, hepatotoxicity, and cytopenias, particularly in renal dysfunction or dosing errors. High-dose oncologic use is associated with severe pancytopenia and transaminitis.[85] Leucovorin is used to mitigate the toxicity of antifolates.[86] Glucarpidase is reserved for severe toxicity with delayed clearance in renal failure, but it is uncommon in rheumatology dosing.[87] Leflunomide The active metabolite of leflunomide, teriflunomide, has a prolonged half-life. Cholestyramine washout (8 g TID for 11 days) accelerates elimination.[60] Undetectable plasma levels are advised before conception in both sexes. Sulfasalazine Overdose is rare; toxicity may present as hypersensitivity, hepatotoxicity, or cytopenias.[88] Management is supportive, with no specific antidote. Biologic DMARDs The primary risks include immunosuppression and infection (eg, tuberculosis, pneumonia, and herpes zoster).[89] Therapy should be discontinued during an active infection and resumed after resolution. Rituximab has been associated with rare cases of PML; no antidote exists.[90] Prompt, individualized toxicity management is essential. Preventive measures, including patient education and monitoring, reduce risk, especially in those with renal or hepatic impairment or polypharmacy. For up-to-date recommendations, consultation with a medical toxicologist or the poison control center is advised.

Pearls and Pitfalls Early DMARD initiation improves outcomes: Starting within 3 months of RA onset reduces joint damage and preserves function. Methotrexate remains the first-line treatment: Weekly dosing with folic acid is standard; SC administration may enhance tolerance and efficacy. Hydroxychloroquine is well tolerated: Safe in pregnancy; requires baseline and periodic eye examinations to detect retinal toxicity. Certolizumab is preferred during pregnancy: Minimal placental transfer makes it the safest biologic option. Infection screening is essential: Screen for tuberculosis and hepatitis B before starting biologics or JAK inhibitors. JAK inhibitors carry boxed warnings: Use cautiously in refractory disease due to increased risks of thrombosis, malignancy, and cardiovascular events. Leflunomide requires drug elimination before conception: Cholestyramine washout is needed for both men and women. Patient education is critical: Reinforce adherence, lab follow-up, and early reporting of symptoms such as fever or cough. Pharmacist and nurse involvement enhances patient safety: Support proper dosing, laboratory coordination, and patient counseling. Common Pitfalls Omitting baseline laboratory parameters or vaccine review increases preventable risks. Using methotrexate in advanced chronic kidney disease without adjustment may lead to severe toxicity. The combination of methotrexate with trimethoprim-sulfamethoxazole may result in severe bone marrow suppression. Delaying infection screening before immunosuppressive therapy may result in reactivation. Assuming all biologics are safe in pregnancy is incorrect; only certolizumab has established safety. Neglecting eye exams while taking hydroxychloroquine can delay the detection of retinal toxicity. Restarting biologics too soon after infection may worsen clinical outcomes. Inadequate early monitoring misses adverse effects that commonly occur within the first 3 to 6 months.

Assuming all biologics are safe in pregnancy is incorrect; only certolizumab has established safety. Neglecting eye exams while taking hydroxychloroquine can delay the detection of retinal toxicity. Restarting biologics too soon after infection may worsen clinical outcomes. Inadequate early monitoring misses adverse effects that commonly occur within the first 3 to 6 months. Effective DMARD therapy requires coordinated interprofessional care to ensure safe monitoring, early detection of toxicity, and optimized treatment outcomes. Rheumatologists initiate and adjust therapy, monitor disease activity, and manage the risks associated with immunosuppression. Primary care providers address comorbidities, support vaccination, and assist with infection screening. Pharmacists assess for drug interactions, confirm dosing accuracy, and counsel on adverse effect prevention. Nurses administer therapy, monitor for complications, reinforce patient education, and provide ongoing follow-up care. Patients and caregivers contribute through adherence, symptom reporting, and contraceptive compliance when applicable. This interprofessional team approach, combined with clear communication among physicians, advanced practice providers, nurses, and pharmacists, decreases adverse effects and improves patient outcomes related to DMARDs.